Dosing has been completed for all study subjects in Desentum’s First-in-Human clinical study of DM-101, a novel allergy vaccine intended for treating birch pollen allergy. Last follow-up visits will be completed during Q2/2021 and study results are expected in Q3/2021.Read more »
Below you can find the latest news releases from Desentum.
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt.Read more »
Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason for suspension is that the corona virus epidemic has brought about restrictions in the operations at the study site.Read more »
The latest open access paper about our hypoallergen development is available at Nature Scientific Reports.Read more »
Desentum is about to initiate a first-in-human clinical trial with its birch pollen hypoallergen designed to improve immunotherapeutic treatment of birch pollen allergy. In a funding round arranged by Springvest Oy, the company raised 4 million euros that it intends to use for funding clinical...Read more »